ReviewJournal of neuro-oncology2017
Current trends in mouse models of glioblastoma.
Review in Journal of neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 111 citations in OpenAlex.
- A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy.Journal of experimental & clinical cancer research : CR · 2021Pooled it
- 3D Bioprinted Blood-Brain-Tumor Barrier Spheroid-Based In Situ Evaluation of Anticancer Compounds Against Glioblastoma: ROS-Producing Ruthenium as a Potential Therapeutic Candidate.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Translational Models for Glioblastoma: Revolutionizing Drug Development and Personalized Medicine through Clinical Insights.Theranostics · 2026Review
- Modeling Glioblastoma with Brain Organoids: New Frontiers in Oncology and Space Research.International journal of molecular sciences · 2025Review
- Evolution of Preclinical Models for Glioblastoma Modelling and Drug Screening.Current oncology reports · 2025Review
- Microtubule actin crosslinking factor 1, a brain tumor oncoprotein (Review).Molecular and clinical oncology · 2025Review
- Current landscape and future directions of targeted-alpha-therapy for glioblastoma treatment.Theranostics · 2025Review
- Review
- Intratumoral Cell Heterogeneity in Patient-Derived Glioblastoma Cell Lines Revealed by Single-Cell RNA-Sequencing.International journal of molecular sciences · 2024Article
- Chlorpromazine overcomes temozolomide resistance in glioblastoma by inhibiting Cx43 and essential DNA repair pathways.Journal of translational medicine · 2024Article
- Article
- Integrating Ataxia Evaluation into Tumor-Induced Hearing Loss Model to Comprehensively Study NF2-Related Schwannomatosis.Cancers · 2024Article
- Speeding up Glioblastoma Cancer Research: Highlighting the Zebrafish Xenograft Model.International journal of molecular sciences · 2024Review
- Preclinical Models and Technologies in Glioblastoma Research: Evolution, Current State, and Future Avenues.International journal of molecular sciences · 2023Review
- Shadow imaging for panoptical visualization of brain tissue in vivo.Nature communications · 2023Article
- Translational Models in Glioma Immunotherapy Research.Current oncology (Toronto, Ont.) · 2023Review
- Locomotion Outcome Improvement in Mice with Glioblastoma Multiforme after Treatment with Anastrozole.Brain sciences · 2023Article
- Evolution-driven crosstalk between glioblastoma and the tumor microenvironment.Cancer biology & medicine · 2023Article
- DGKB mediates radioresistance by regulating DGAT1-dependent lipotoxicity in glioblastoma.Cell reports. Medicine · 2023Article
- Discovering Glioma Tissue through Its Biomarkers' Detection in Blood by Raman Spectroscopy and Machine Learning.Pharmaceutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Glioblastoma is the most deadly brain tumor type and is characterized by a severe and high rate of angiogenesis, remaining an incurable disease in the majority of cases. Mechanistic understanding of glioblastoma initiation and progression is complicated by the complexity of genetic and/or environmental initiating events and lack of clarity regarding the cell or tissue of origin. To determine these mechanisms, mouse models that recapitulate the molecular and histological characteristics of glioblastoma are required. Unlike in other malignancies, viral-mediated mouse models of glioblastoma rather than chemically induced mouse models have been developed because of its sensitivity to viruses. Based on recent molecular analyses reported for human glioblastoma, this review critically evaluates genetically engineered, xenograft, allograft, viral-mediated, and chemically induced mouse models of glioblastoma. Further, we focus on the clinical value of these models by examining their contributions to studies of glioblastoma prevention, tumorigenesis, and chemoresistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.